AbbVie files etentamig application: what it means for AbbVie stock

Published on 10/28/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Etentamig reached a 74.00 percent response rate versus 45.70 percent in CERVINO. AbbVie stock trades at EUR 256.55 on October 28, 2026.

Clinical evidence supports filing

AbbVie submitted the etentamig application on October 27, 2026.
The CERVINO study reported a 74.00 percent response rate versus 45.70 percent for standard therapies.
AbbVie stock trades at EUR 256.55 at 10:41 a.m. CET at Lang & Schwarz on October 28, 2026.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) submitted a biologics license application for etentamig to the U.S. Food and Drug Administration on October 27, 2026, according to the AbbVie release distributed by PR Newswire. The filing covers adults with relapsed or refractory multiple myeloma and gives AbbVie a new regulatory milestone in blood cancer.

CERVINO provides the key evidence

The application is supported by the global, randomized Phase 3 CERVINO study, which enrolled 393 patients who had received at least two prior lines of treatment. Etentamig produced an overall response rate of 74.00 percent, compared with 45.70 percent for investigator-selected standard available therapies.

The same study showed a 60.00 percent reduction in the risk of disease progression or death versus standard therapy. The treatment was administered with a single step-up dose followed by monthly dosing, a schedule AbbVie presents as a potential advantage for treatment delivery.

Safety remains part of the test

The results also include countervailing safety figures. Grade 3 or 4 infections occurred in 27.70 percent of patients receiving etentamig versus 19.20 percent in the comparison group, while treatment-related discontinuations were 3.60 percent versus 14.00 percent.

For investors, the filing expands AbbVie's oncology pipeline but does not yet represent a marketing approval. The FDA must review the application before etentamig can become an approved treatment, so the clinical benefit and safety balance remain central to the next stage.

Stock trades at EUR 256.55

AbbVie stock was trading at EUR 256.55 at Lang & Schwarz on October 28, 2026, at 10:41 a.m. CET. The SEC identifies AbbVie as listed on the New York Stock Exchange under ticker ABBV.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.